

FORM LAMPIRAN PENGAJUAN PROMO MATERIAL MARKETING

A. INFORMASI AJUAN PROMAT

JENIS AJUAN PROMAT ☒ NEW PROMAT ☐ REPEAT ORDER ☐ SPECIAL GIMMICK ☐ PROMAT EVENT / RTD

JENIS PROMAT ☐ INVENTARIS ☐ NON INVENTARIS

NAMA PROMAT : ROLL BANNER RIBAN UKURAN 85 X 200 CM

QUANTITY : 3

MATERIAL PROMAT : ALBATROS

KETERANGAN :

BUDGET PROMAT : X BANNER RIBAN (MKTMER26-PR045) : RP.300.000, X BANNER EPILEPSI (MKTMER26-PR039) : RP.300.000
X BANNER EDUKASI ALZHEIMER (MKTMER26-PR042) : RP.300.000

B. RENCANA PENGGUNAAN PROMAT

NO	NAMA PROMAT	QTY	KETERANGAN PENGGUNAAN	PERIODE
1	ROLL BANNER RIBAN UKURAN 85 X 200 CM	1	PIN PERDOSNI	Apr-26
2	ROLL BANNER RIBAN UKURAN 85 X 200 CM	1	JAKNEWS	MEI 2026
3	ROLL BANNER RIBAN UKURAN 85 X 200 CM	1	CNE	JULI 2026
4				
5				
TOTAL		3		

C. INFORMASI STOCK PROMAT

PENGGUNAAN PROMAT**

** isi dengan promat dengan type / jenis yang sama

NO	NAMA PROMAT	QTY STOCK AKHIR	QTY PENGGUNAAN	TOTAL	AVG	KETERANGAN
1						
2						
3						
4						
5						
6						
7						
8						
TOTAL		0	0	0		

ANALISA AJUAN

*diisi oleh Marketing Support

- Belum pernah ada pembuatan banner untuk produk tersebut.
- History Budget tercantum belum pernah digunakan

Tanggal Pengajuan : 02 APR 2026

Diajukan oleh,  Product Executive	Mengetahui,  Product Manager	Di koreksi oleh,  Marketing Support	Mengetahui,  MMS	Menyetujui,  Marketing Director
--	---	--	--	--


ARTWORK DESIGN STANDARD BROCHURE

Date of use: _____
(DD-MM-YYYY)

ROLL BANNER RIBAN		
Dimension / size 85 x 200 cm		
Material	Vernish	Quantity
ALBATROS		

Front Side			Back Side	Mersi Address
Type Font			Type Font	Type Font
Product Name	Tagline Font	Another Font	Another Font	Another Font

SKETCHES



Handwritten signature and date: 27/3/20


Not at scale - size in mm

Cut	Logo Front Side	Logo Back Side						Color Process	Offset Code	Material Code
										

Release	Drawing by	Approved by
Date	26/3/2026	
Signature		
Name	Afy	

RIBAN®

Rivaroxaban 20 mg



Modern Solutions for Clot Prevention

-  Proven Protection against DVT, Pulmonary Embolism and Fibrilasi Atrium Nonvalvular.^{1,2,3,5}
-  Convenient Once- Daily Dosing Regimen.^{3,4,5}
-  Well- Tolerated with a Trusted Safety Profile.^{1,2,6}
-  Rapid onset of action.⁶



FOR MEDICAL PRESCRIPTION ONLY

References:

- Patel KR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883-891.
- Juglar JA, Chung MK, Arribas AL, Benjamin EJ, Chrys JP, Crum BM, et al. 2023 ACC/AHA/ACCP/WHF guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2024 Jun 25;1(1):109-279.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). Pedoman tata laksana fibrilasi atrium nonvalvular. Edisi kedua. Jakarta Pusat: PT Trans Medical International; 2019. ISBN: 978-602-72719-1-3.
- Kakkos SK, Gohel M, Bækgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. *Eur J Vasc Endovasc Surg*. 2021;61(1):9-62.
- Hindriks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. *Eur Heart J*. 2021;42(5):372-498.
- Stampfuss J, Kubitz G, Becka M, Musch W. The effect of food on the pharmacokinetics and pharmacodynamics of rivaroxaban. *Int J Clin Pharmacol Ther*. 2013;51(7):549-561.